Physician profile
Mark B Odaniel
NPI 1164529640
$29,764.87
in general payments reported to CMS, 2019-2025
23 companies · $579 in 2025
The $579 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,217 · 2020: $2,917 · 2021: $2,916 · 2022: $3,967 · 2023: $14K · 2024: $2,632 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $2,296 · Travel and Lodging: $1,502 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,750.00 |
| Food and Beverage | $2,295.54 |
| Travel and Lodging | $1,501.88 |
| Education | $200.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,747.64 | 2021-2024 | |
| Allergan, INC. | $5,590.26 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $798.88 | 2019-2024 | Austedo Xr, Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $604.86 | 2019-2025 | Invega Sustenna, Spravato, Invega |
| Alkermes, INC. | $408.21 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $361.01 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $360.72 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $210.04 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $117.30 | 2019-2023 | Jornay Pm |
| Neurocrine Biosciences, INC. | $117.10 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $113.46 | 2019-2024 | Hetlioz, Fanapt |
| Luye Pharma (USA) LTD. | $48.94 | 2025 | Erzofri Extended-Release |
| Indivior INC. | $45.36 | 2019-2024 | |
| Almatica Pharma LLC | $41.61 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $37.87 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $32.80 | 2022 | |
| Merz North America, INC. | $23.95 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.15 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $19.37 | 2022 | |
| Janssen Biotech, INC. | $18.91 | 2023 | |
| Neuronetics, INC. | $18.28 | 2020 | |
| Axsome Therapeutics, INC. | $13.20 | 2023 | Auvelity |
| Noven Therapeutics, LLC | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Odaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.